The United States has assured Uganda of continued funding for HIV/AIDS research and treatment despite the recent storm over the passing of the controversial anti-homosexuality Act.
Dan Travis, the public affairs officer at the US embassy in Kampala, said Uganda has been allocated $323m (about sh805b) for this fiscal year 2014 under the US President’s Emergency Plan for AIDS Relief (PEPFAR).
At least 60% is dedicated to treatment while 40% is earmarked to accelerate prevention projects like safe male medical circumcision and condom supply.
This means HIV funding from US has remained the same as last year. Consequently, the 507,000 HIV positive Ugandans who get free anti-retroviral (ARV) drugs from PEPFAR-supported agencies have no cause to worry.
“The key thing is not the money but the number of people who are supported so they can work, study and make a contribution to their families,” Travis observed.
He was addressing health reporters who underwent training in health reporting at the US embassy in Nsambya, a Kampala suburb on Thursday.
Launched in 2003, PEPFAR’s massive funding has made ARVs widely available, saving millions of lives worldwide. According to a 2009 study published in Annals of Internal Medicine, the program had averted about 1.1 million deaths in Africa and reduced the death rate due to AIDS in the countries involved by more than 10%.
In Uganda, where HIV prevalence increased from 6.4% in 2006 to 7.3% currently, the US has injected over $2.3b (about sh5.6 trillion) to fight HIV in the last decade.
Of the 577,000 Ugandans currently on ARVS, 87% (507,000) are funded by PEPFAR.
Full text of article available at link below –